Can’t Stop Buying This Dividend Juggernaut: ABBV Growth
A long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
Choosing the right funds for a retirement portfolio requires balance of cost and coverage. Review 2024 options and practical selection tips.
26,319 articlesA long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
USA Rare Earth's stock dropped 15.7% in February as broad markets wobbled, but March brought signs of life. This guid...
Investors are watching Summit Midstream (SMC) 2026 Q1 earnings for clues on cash flow, debt, and future distributions...
Qualcomm is shifting focus from phones to AI compute, targeting massive new markets. This article breaks down the pla...
MercadoLibre's fourth-quarter results showed strong revenue growth, but a notable drop in profitability. This article...
Amentum faces a pivotal Q2 2026 earnings season. This deep dive breaks down backlog, margins, and guidance, with prac...
Investors woke up to a surge in Qualcomm stock after the company outlined bold AI-backed growth targets. This article...
DSGR's Q4 2025 results sparked questions about growth, margins, and 2026 guidance. This deep dive explains what the n...
JPMorgan expands its institutional cash toolbox by assigning Ethereum and Solana to separate roles in a new on-chain ...
Chip stocks rise on liquidity-driven rotations, but Morgan Stanley’s CIO cautions this may be near peak rather than a...
CrowdStrike’s ARR growth has reaccelerated, but does that make the stock a buy? This guide breaks down ARR health, ma...
Stran’s Q1 2026 earnings reveal a mix of steady demand and evolving margins. This article breaks down the numbers, of...